171 related articles for article (PubMed ID: 27053325)
1. Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers.
Cho DY; Shen JH; Lemler SM; Skaar TC; Li L; Blievernicht J; Zanger UM; Kim KB; Shin JG; Flockhart DA; Desta Z
Drug Metab Pharmacokinet; 2016 Apr; 31(2):107-16. PubMed ID: 27053325
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Cytochrome P450 2B6 Activity by Voriconazole Profiled Using Efavirenz Disposition in Healthy Volunteers.
Desta Z; Metzger IF; Thong N; Lu JB; Callaghan JT; Skaar TC; Flockhart DA; Galinsky RE
Antimicrob Agents Chemother; 2016 Nov; 60(11):6813-6822. PubMed ID: 27600044
[TBL] [Abstract][Full Text] [Related]
3. CYP2B6 Genotype-Dependent Inhibition of CYP1A2 and Induction of CYP2A6 by the Antiretroviral Drug Efavirenz in Healthy Volunteers.
Metzger IF; Dave N; Kreutz Y; Lu JBL; Galinsky RE; Desta Z
Clin Transl Sci; 2019 Nov; 12(6):657-666. PubMed ID: 31339646
[TBL] [Abstract][Full Text] [Related]
4. Efavirenz primary and secondary metabolism in vitro and in vivo: identification of novel metabolic pathways and cytochrome P450 2A6 as the principal catalyst of efavirenz 7-hydroxylation.
Ogburn ET; Jones DR; Masters AR; Xu C; Guo Y; Desta Z
Drug Metab Dispos; 2010 Jul; 38(7):1218-29. PubMed ID: 20335270
[TBL] [Abstract][Full Text] [Related]
5. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.
Robertson SM; Maldarelli F; Natarajan V; Formentini E; Alfaro RM; Penzak SR
J Acquir Immune Defic Syndr; 2008 Dec; 49(5):513-9. PubMed ID: 18989234
[TBL] [Abstract][Full Text] [Related]
6. Effects of clopidogrel and itraconazole on the disposition of efavirenz and its hydroxyl metabolites: exploration of a novel CYP2B6 phenotyping index.
Jiang F; Desta Z; Shon JH; Yeo CW; Kim HS; Liu KH; Bae SK; Lee SS; Flockhart DA; Shin JG
Br J Clin Pharmacol; 2013 Jan; 75(1):244-53. PubMed ID: 22554354
[TBL] [Abstract][Full Text] [Related]
7. Isoniazid mediates the CYP2B6*6 genotype-dependent interaction between efavirenz and antituberculosis drug therapy through mechanism-based inactivation of CYP2A6.
Court MH; Almutairi FE; Greenblatt DJ; Hazarika S; Sheng H; Klein K; Zanger UM; Bourgea J; Patten CJ; Kwara A
Antimicrob Agents Chemother; 2014 Jul; 58(7):4145-52. PubMed ID: 24820076
[TBL] [Abstract][Full Text] [Related]
8. Efavirenz Metabolism: Influence of Polymorphic CYP2B6 Variants and Stereochemistry.
Wang PF; Neiner A; Kharasch ED
Drug Metab Dispos; 2019 Oct; 47(10):1195-1205. PubMed ID: 31324697
[TBL] [Abstract][Full Text] [Related]
9. Contribution of N-glucuronidation to efavirenz elimination in vivo in the basal and rifampin-induced metabolism of efavirenz.
Cho DY; Ogburn ET; Jones D; Desta Z
Antimicrob Agents Chemother; 2011 Apr; 55(4):1504-9. PubMed ID: 21282425
[TBL] [Abstract][Full Text] [Related]
10. Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro.
Desta Z; Saussele T; Ward B; Blievernicht J; Li L; Klein K; Flockhart DA; Zanger UM
Pharmacogenomics; 2007 Jun; 8(6):547-58. PubMed ID: 17559344
[TBL] [Abstract][Full Text] [Related]
11. Cytochrome P450 2B6 activity as measured by bupropion hydroxylation: effect of induction by rifampin and ethnicity.
Loboz KK; Gross AS; Williams KM; Liauw WS; Day RO; Blievernicht JK; Zanger UM; McLachlan AJ
Clin Pharmacol Ther; 2006 Jul; 80(1):75-84. PubMed ID: 16815319
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Effect of Rifampicin-Based Anti-TB Regimen Coadministration on the Pharmacokinetic Parameters of Efavirenz and 8-Hydroxy-Efavirenz in Ethiopian Patients.
Habtewold A; Aklillu E; Makonnen E; Amogne W; Yimer G; Aderaye G; Bertilsson L; Owen JS; Burhenne J
J Clin Pharmacol; 2016 Dec; 56(12):1538-1549. PubMed ID: 27125860
[TBL] [Abstract][Full Text] [Related]
13. The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.
Ward BA; Gorski JC; Jones DR; Hall SD; Flockhart DA; Desta Z
J Pharmacol Exp Ther; 2003 Jul; 306(1):287-300. PubMed ID: 12676886
[TBL] [Abstract][Full Text] [Related]
14. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
[TBL] [Abstract][Full Text] [Related]
15. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers.
Yenny ; Nafrialdi ; Djoerban Z; Setiabudy R
Int J Clin Pharmacol Ther; 2011 Feb; 49(2):162-8. PubMed ID: 21255533
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance.
Kwara A; Cao L; Yang H; Poethke P; Kurpewski J; Tashima KT; Mahjoub BD; Court MH; Peloquin CA
Pharmacotherapy; 2014 Mar; 34(3):265-71. PubMed ID: 24420746
[TBL] [Abstract][Full Text] [Related]
18. Population Pharmacokinetic Modeling To Estimate the Contributions of Genetic and Nongenetic Factors to Efavirenz Disposition.
Robarge JD; Metzger IF; Lu J; Thong N; Skaar TC; Desta Z; Bies RR
Antimicrob Agents Chemother; 2017 Jan; 61(1):. PubMed ID: 27799204
[TBL] [Abstract][Full Text] [Related]
19. Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation.
Watanabe T; Saito T; Rico EMG; Hishinuma E; Kumondai M; Maekawa M; Oda A; Saigusa D; Saito S; Yasuda J; Nagasaki M; Minegishi N; Yamamoto M; Yamaguchi H; Mano N; Hirasawa N; Hiratsuka M
Biochem Pharmacol; 2018 Oct; 156():420-430. PubMed ID: 30201214
[TBL] [Abstract][Full Text] [Related]
20. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity.
Kharasch ED; Mitchell D; Coles R
J Clin Pharmacol; 2008 Apr; 48(4):464-74. PubMed ID: 18287571
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
